WO2008015423A1 - N-oxydes de quinoléine et de quinoxaline en tant qu'inhibiteurs de la chk-1 - Google Patents

N-oxydes de quinoléine et de quinoxaline en tant qu'inhibiteurs de la chk-1 Download PDF

Info

Publication number
WO2008015423A1
WO2008015423A1 PCT/GB2007/002918 GB2007002918W WO2008015423A1 WO 2008015423 A1 WO2008015423 A1 WO 2008015423A1 GB 2007002918 W GB2007002918 W GB 2007002918W WO 2008015423 A1 WO2008015423 A1 WO 2008015423A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound according
hydrogen
cyano
carbocyclic
Prior art date
Application number
PCT/GB2007/002918
Other languages
English (en)
Inventor
Robert George Boyle
Stuart Travers
Original Assignee
Sentinel Oncology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0615293A external-priority patent/GB0615293D0/en
Application filed by Sentinel Oncology Limited filed Critical Sentinel Oncology Limited
Publication of WO2008015423A1 publication Critical patent/WO2008015423A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This invention relates to N-oxide compounds that can be reduced under hypoxic cellular conditions such as those found in many solid tumour cells, and to compounds that inhibit or modulate the activity of Chk-1 kinase and which are activated under hypoxic conditions. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.
  • Chk-1 is a serine/threonine kinase involved in the induction of cell cycle checkpoints in response to DNA damage and replicative stress and hypoxia (see Hammond et al, Cancer Letters, 238, (2006), 161-167).
  • Cell cycle checkpoints are regulatory pathways that control the order and timing of cell cycle transitions. They ensure that critical events such as DNA replication and chromosome segregation function correctly. The regulation of these cell cycle checkpoints is of considerable importance in determining the manner in which tumour cells respond to chemotherapy and radiation therapy.
  • Many anti-cancer drugs achieve their anti-cancer effects by causing DNA damage but resistance to such drugs is a significant problem.
  • One mechanism responsible for drug resistance is attributed to the prevention of cell cycle progression through the control of critical activation of a checkpoint pathway.
  • Chk-1 plays a role in regulating cell cycle arrest by phosphorylating the phosphatase cdc25 on Serine 216, which may be involved in preventing activation of cdc2/cyclin B and initiating mitosis. Therefore, it is envisaged that inhibition of Chk-1 should enhance DNA damaging agents by initiating mitosis before DNA repair is complete and thereby causing tumour cell death.
  • Chkl inhibitors may be useful in treating tumour cells in which the Gl/S DNA damage checkpoint has been lost and where the tumours therefore rely on the G2/M DNA damage checkpoint exclusively to correct any DNA damage.
  • tumours are those arising from or associated with mutations in the p53 gene, a tumour suppressor gene found in about 50% of all human cancers (see for example Hahn et ⁇ /., "Rules for making human tumor cells” N Engl J Med 2002; 347: 1593-603 and Hollstein et al, "p53 mutations in human cancers. Science 1991; 253: 49-53).
  • Chkl inhibitors should be of particular value in treating p53 negative or mutated tumours.
  • WO 03/10444 and WO 2005/072733 disclose aryl/heteroaryl urea compounds as Chk-1 kinase inhibitors.
  • US2005/215556 discloses macrocyclic ureas as kinase inhibitors.
  • WO 02/070494, WO2006014359 and WO2006021002 disclose aryl and heteroaryl ureas as Chk-1 inhibitors.
  • Solid tumours which make up more than 90% of all human cancers, typically have areas of very low oxygenation, or hypoxia (Brown, Molecular Medicine Today, 2000 (vol 6), 157-161).
  • hypoxia Brown, Molecular Medicine Today, 2000 (vol 6), 157-161).
  • the aggressive growth of solid tumours exerts pressure on surrounding vasculature to maintain a sufficient supply of blood and nutrients to these cells.
  • the growing distance of cells from the blood supply ultimately leads to regions of very low oxygen concentrations that are said to be hypoxic.
  • tumour hypoxia including: resistance to killing by ionising radiation (Movsas et al., Cancer, 2000, 89, 2018; Rudat et al., Radiother.
  • tumour hypoxia is a key factor associated with tumour aggressiveness, its existence provides an opportunity that has been exploited by tumour targeting agents (Anti- Cancer Agents in Medicinal Chemistry, 2006, 6, 281-286).
  • Tirapazamine TPZ - Denny and
  • TPZ TPZ cannot be given at doses sufficient enough to fully exploit tumour hypoxia.
  • Quinoxaline dioxides are known to undergo bioreductions under hypoxia causing DNA damage (Scheme A) - see for example (i) Bioorg. Med. Chem. 2001, 9, 2395-2401, (ii) Chem. Res. Toxicol. 2004, 17(11), 1399-1405 (TX-402), and (iii) Mutagenesis 2005, 20(3), 165-171 (Q85).
  • the ease of bioreduction is governed by the one electron reduction potentials (El) of the dioxide and can be influenced by the substituents on the ring: see the article in Zhongguo Yaowu Huaxue Zazhi 1997, 7(3), 157-161).
  • the presence of electron withdrawing groups as subsituents makes the E 1/2 more positive and hence potentially more selective for hypoxia.
  • the one-electron reduction potential is a key parameter for the successful bioreduction under hypoxia is the E(I). If the E(I) value is too high, reduction will not be limited to hypoxic conditions, and the compound may be toxic to normal cells. Conversely, if the E(I) value is too low, the rate of reduction may be too slow to provide therapeutic benefit.
  • the optimal range for hypoxic selective bioreduction appears to be between about -45OmV and -51OmV. Values higher than -30OmV have been found to induce aerobic toxicity, and values lower than -51OmV reduce slowly (Hay MP. J. Med. Chem., 2003, 46:169-182). It has been reported that mono-N-oxides of substituted 3-ammo-l,2,4-benzotriazine 1,4-dioxides have E(I) values in the range required for hypoxic bioreduction, and that these values change in line with the substitution patterns (Anderson RF. Org. Biomol. Chem., 2005, 3:2167-2174).
  • tumour cells and in particular hypoxic tumour cells.
  • the compounds will act against tumour cells by a two step mechanism involving firstly, the selective induction of DNA damage under tumour hypoxia, and secondly the inhibition of proteins essential for DNA repair. Importantly, both of these steps are achieved from the action of a single molecule that is inert under normal (aerobic) conditions.
  • Such a mechanism provides a means for selective activation in the tumour, the potential for synergy with DNA damage and the potential for an overall increased therapeutic index.
  • the invention provides a compound of the formula (1):
  • Y 1 and Y 2 are both N + -CT or one of Y 1 and Y 2 is N and the other is N + -CT;
  • G is CH 2 , O, NH, NHCO or CONH;
  • A is a group (CH 2 ) n where n is 1 to 4 provided that when G is O or NH, n is at least 2;
  • V is nitrogen or a group CR ;
  • V 3 is nitrogen or a group CR 5 ;
  • V 4 is nitrogen or CH; provided that no more than two of V 2 , V 3 and V 4 are nitrogen;
  • R 1 and R 2 are the same or different and each is hydrogen or a substituent R 6 ;
  • R 3 and R 4 are the same or different and each is hydrogen or C 1-4 alkyl; or R 3 and R 4 together with the nitrogen atom to which they are attached form an azetidine, pyrrolidine, piperidine, piperazine, N-methylpiperazine or morpholine group; provided that when Q is N + -O " , then R 3 and R 4 are both other than hydrogen;
  • R 5 is hydrogen or a substituent R 6 ;
  • R 6 is halogen; hydroxy; trifluoromethyl; cyano; nitro; amino; mono- or di-d- 4 hydrocarbylamino; a carbocyclic or heterocyclic group having from 3 to 12 ring members and optionally substituted by one or more substituents R 7 ; or a group R a -R b ;
  • R a is a bond, O, CO, X 1 C(X 2 ), C(X 2 JX 1 , X 1 C(X 2 JX 1 , S, SO, SO 2 , NR 0 , SO 2 NR 0 OrNR 0 SO 2 ;
  • R b is: • hydrogen
  • a C 1-12 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy; oxo; halogen; cyano; nitro; carboxy; amino; mono- or di-C ⁇ s non-aromatic hydrocarbylamino; and carbocyclic and heterocyclic groups having from 3 to 12 ring members optionally substituted by one or more substituents R 7 ; wherein one or more carbon atoms of the C 1-12 hydrocarbyl group may optionally be replaced by O, S, SO 5 SO 2 , NR 0 , X 1 C(X 2 ), C(X ⁇ X 1 or X 1 CQi 2 JX 1 ; R c is R b , hydrogen or C 1-4 hydrocarbyl;
  • Y 1 and Y 2 are both N + -O ' .
  • Such compounds are designated herein as compounds of the formula (Ia).
  • one of Y 1 and Y 2 is N and the other is N + -O " .
  • Such compounds are designated herein as compounds of the formula (Ib).
  • the invention also provides inter alia:
  • a method of treating a cancer which method comprises administering to a subject need thereof a therapeutically effective amount of a compound of formula (1), optionally together with another anti-cancer agent or radiation therapy.
  • a method of causing DNA damage in hypoxic tumour cells which method comprises bringing a compound of the formula (1) as defined herein into contact with the hypoxic tumour cells.
  • a compound of the formula (1) as defined herein for use in enhancing a therapeutic effect of radiation therapy or chemotherapy in the treatment of a proliferative disease such as cancer.
  • a method for the prophylaxis or treatment of a proliferative disease such as cancer which method comprises administering to a patient in combination with radiotherapy or chemotherapy a compound of the formula (1) as defined herein.
  • a compound of the formula (1) as defined herein for use in the treatment of a patient suffering from a p53 negative or mutated tumour.
  • a method for the treatment of a patient e.g. a human patient suffering from a p53 negative or mutated tumour, which method comprises administering to the patient a therapeutically effective amount of a compound of the formula (1).
  • a pharmaceutical composition comprising a compound of the formula (1) as defined herein and a pharmaceutically acceptable carrier. • A compound of the formula (1) as defined herein for use in medicine.
  • references to a compound of formula (1) includes formula (Ia), (Ib), and all other subgroups thereof as defined herein, and the term 'subgroups' includes all preferences, embodiments, examples and particular compounds defined herein.
  • references to "carbocyclic” and “heterocyclic” groups as used herein shall, unless the context indicates otherwise, include both aromatic and non-aromatic ring systems.
  • such groups may be monocyclic or bicyclic and may contain, for example, 3 to 12 ring members, more usually 5 to 10 ring members.
  • monocyclic groups are groups containing 3, 4, 5, 6, 7, and 8 ring members, more usually 3 to 7, and preferably 5 or 6 ring members.
  • Examples of bicyclic groups are those containing 8, 9, 10, 11 and 12 ring members, and more usually 9 or 10 ring members.
  • the carbocyclic or heterocyclic groups can be aryl or heteroaryl groups having from 5 to 12 ring members, more usually from 5 to 10 ring members.
  • aryl refers to a carbocyclic group having aromatic character and the term “heteroaryl” is used herein to denote a heterocyclic group having aromatic character.
  • aryl and heteroaryl embrace polycyclic (e.g. bicyclic) ring systems wherein one or more rings are non-aromatic, provided that at least one ring is aromatic. In such polycyclic systems, the group may be attached by the aromatic ring, or by a non-aromatic ring.
  • non-aromatic group embraces unsaturated ring systems without aromatic character, partially saturated and fully saturated carbocyclic and heterocyclic ring systems.
  • fully saturated refers to rings where there are no multiple bonds between ring atoms.
  • Saturated carbocyclic groups include cycloalkyl groups as defined below.
  • Partially saturated carbocyclic groups include cycloalkenyl groups as defined below, for example cyclopentenyl, cycloheptenyl and cyclooctenyl.
  • heteroaryl groups are monocyclic and bicyclic groups containing from five to twelve ring members, and more usually from five to ten ring members.
  • the heteroaryl group can be, for example, a five membered or six membered monocyclic ring or a bicyclic structure formed from fused five and six membered rings or two fused six membered rings. Each ring may contain up to about four heteroatoms typically selected from nitrogen, sulphur and oxygen.
  • the heteroaryl ring will contain up to 3 heteroatoms, more usually up to 2, for example a single heteroatom.
  • the heteroaryl ring contains at least one ring nitrogen atom.
  • the nitrogen atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially non-basic as in the case of an indole or pyrrole nitrogen. In general the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents of the ring, will be less than five.
  • Examples of five membered heteroaryl groups include but are not limited to pyrrole, furan, thiophene, imidazole, furazan, oxazole, oxadiazole, oxatriazole, isoxazole, thiazole, isothiazole, pyrazole, triazole and tetrazole groups.
  • Examples of six membered heteroaryl groups include but are not limited to pyridine, pyrazine, pyridazine, pyrimidine and triazine.
  • a bicyclic heteroaryl group may be, for example, a group selected from: a) a benzene ring fused to a 5- or 6-membered ring containing 1 , 2 or 3 ring heteroatoms; b) a pyridine ring fused to a 5- or 6-membered ring containing 1 , 2 or 3 ring heteroatoms; c) a pyrimidine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; d) a pyrrole ring fused to a a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; e) a pyrazole ring fused to a a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; f) a pyrazine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; g) an imidazole ring fused to
  • a thiophene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms 1) a thiophene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; m) a furan ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; n) a cyclohexyl ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; and o) a cyclopentyl ring fused to a 5- or 6-membered ring containing I 5 2 or 3 ring heteroatoms.
  • bicyclic heteroaryl groups containing a six membered ring fused to a five membered ring include but are not limited to benzfuran, benzthiophene, benzimidazole, benzoxazole, benzisoxazole, benzthiazole, benzisothiazole, isobenzofuran, indole, isoindole, indolizine, indoline, isoindoline, purine (e.g. adenine, guanine), indazole, benzodioxole and pyrazolopyridine groups.
  • bicyclic heteroaryl groups containing two fused six membered rings include but are not limited to quinoline, isoquinoline, chroman, thiochroman, chromene, isochromene, chroman, isochroman, benzodioxan, quinolizine, benzoxazine, benzodiazine, pyridopyridine, quinoxaline, quinazoline, cinnoline, phthalazine, naphthyridine and pteridine groups.
  • poly cyclic aryl and heteroaryl groups containing an aromatic ring and a non-aromatic ring examples include tetrahydronaphthalene, tetrahydroisoquinoline, tetrahydroquinoline, dihydrobenzothiene, dihydrobenzofuran, 2,3-dihydro- benzo[l,4]dioxine, benzo[l,3]dioxole, 4,5,6,7-tetrahydrobenzofuran, indoline and indane groups.
  • carbocyclic aryl groups examples include phenyl, naphthyl, indenyl, and tetrahydronaphthyl groups.
  • non-aromatic heterocyclic groups are groups having from 3 to 12 ring members, more usually 5 to 10 ring members. Such groups can be monocyclic or bicyclic, for example, and typically have from 1 to 5 heteroatom ring members (more usually 1, 2, 3 or 4 heteroatom ring members), usually selected from nitrogen, oxygen and sulphur.
  • the heterocylic groups can contain, for example, cyclic ether moieties (e.g as in tetrahydrofuran and dioxane), cyclic thioether moieties (e.g. as in tetrahydrothiophene and dithiane), cyclic amine moieties (e.g. as in pyrrolidine), cyclic sulphones (e.g. as in sulpholane and sulpholene), cyclic sulphoxides, cyclic sulphonamides and combinations thereof (e.g. thiomorpholine).
  • Other examples of non-aromatic heterocyclic groups include cyclic amide moieties (e.g. as in pyrrolidone) and cyclic ester moieties (e.g. as in butyrolactone).
  • Examples of monocyclic non-aromatic heterocyclic groups include 5-, 6-and 7- membered monocyclic heterocyclic groups.
  • Particular examples include morpholine, thiomorpholine and its S-oxide and S,S-dioxide, piperidine (e.g. 1-piperidinyl, 2- piperidinyl, 3-piperidinyl and 4-piperidinyl), N-alkyl piperidines such as N-methyl piperidine, piperidone, pyrrolidine (e.g.
  • non-aromatic carbocyclic groups include cycloalkane groups such as cyclohexyl and cyclopentyl, cycloalkenyl groups such as cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl, as well as cyclohexadienyl, cyclooctatetraene, tetrahydronaphthenyl and decalinyl.
  • halogen substituents include fluorine, chlorine, bromine and iodine. Fluorine and chlorine are particularly preferred.
  • hydrocarbyl is a generic term encompassing aliphatic, alicyclic and aromatic groups having an all-carbon backbone, except where otherwise stated. In certain cases, as defined herein, one or more of the carbon atoms making up the carbon backbone may be replaced by a specified atom or group of atoms.
  • hydrocarbyl groups include alkyl, cycloalkyl, cycloalkenyl, carbocyclic aryl, alkenyl, alkynyl, cycloalkylalkyl, cycloalkenylalkyl, and carbocyclic aralkyl, aralkenyl and aralkynyl groups. Such groups can be unsubstituted or, where stated, can be substituted by one or more substituents as defined herein.
  • the examples and preferences expressed below apply to each of the hydrocarbyl substituent groups or hydrocarbyl-containing substituent groups referred to in the various definitions of substituents for compounds of the formula (I) unless the context indicates otherwise.
  • the hydrocarbyl groups can have up to eight carbon atoms, unless the context requires otherwise.
  • C 1-6 hydrocarbyl groups such as C 1-4 hydrocarbyl groups (e.g. C 1-3 hydrocarbyl groups or C 1-2 hydrocarbyl groups), specific examples being any individual value or combination of values selected from C 1 , C 2 , C 3 , C 4 , Cs, C 6 , C 7 and C 8 hydrocarbyl groups.
  • alkyl covers both straight chain and branched chain alkyl groups.
  • alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 2-methyl butyl, 3-methyl butyl, and n-hexyl and its isomers.
  • C 1-6 alkyl groups such as C 1-4 alkyl groups (e.g. C 1-3 alkyl groups or C 1-2 alkyl groups).
  • cycloalkyl groups are those derived from cyclopropane, cyclobutane, cyclopentane, cyclohexane and cycloheptane. Within the sub-set of cycloalkyl groups the cycloalkyl group will have from 3 to 8 carbon atoms, particular examples being C 3-6 cycloalkyl groups.
  • alkenyl groups include, but are not limited to, ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), isopropenyl, butenyl, buta-l,4-dienyl, pentenyl, and hexenyl.
  • alkenyl groups will have 2 to 8 carbon atoms, particular examples being C 2-6 alkenyl groups, such as C 2-4 alkenyl groups.
  • cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl and cyclohexenyl. Within the sub-set of cycloalkenyl groups the cycloalkenyl groups have from 3 to 8 carbon atoms, and particular examples are C 3-6 cycloalkenyl groups.
  • alkynyl groups include, but are not limited to, ethynyl and 2-propynyl (propargyl) groups. Within the sub-set of alkynyl groups having 2 to 8 carbon atoms, particular examples are C 2-6 alkynyl groups, such as C 2-4 alkynyl groups.
  • carbocyclic aryl groups include substituted and unsubstituted phenyl, naphthyl, indane and indene groups.
  • cycloalkylalkyl, cycloalkenylalkyl, carbocyclic aralkyl, aralkenyl and aralkynyl groups include phenethyl, benzyl, styryl, phenylethynyl, cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclopropylmethyl and cyclopentenylmethyl groups.
  • one or more carbon atoms of a hydrocarbyl group may optionally be replaced by O 5 S, SO, SO 2 , NR 0 , X 1 C(X 2 ), C(X 2 )X* or X 1 C(X ⁇ X 1 (or a sub-group thereof) wherein X 1 and X 2 are as hereinbefore defined, provided that at least one carbon atom of the hydrocarbyl group remains.
  • I 5 2, 3 or 4 carbon atoms of the hydrocarbyl group may be replaced by one of the atoms or groups listed, and the replacing atoms or groups may be the same or different.
  • the number of linear or backbone carbon atoms replaced will correspond to the number of linear or backbone atoms in the group replacing them.
  • groups in which one or more carbon atom of the hydrocarbyl group have been replaced by a replacement atom or group as defined above include ethers and thioethers (C replaced by O or S), amides, esters, thioamides and thioesters (C-C replaced by X 1 C(X 2 ) or C(X 2 )X ! ), sulphones and sulphoxides (C replaced by SO or SO 2 ), amines (C replaced by NR C ). Further examples include ureas, carbonates and carbamates (C-C-C replaced by X 1 C(X 2 )X 1 ).
  • the two hydrocarbyl substituents may, together with the nitrogen atom to which they are attached, and optionally with another heteroatom such as nitrogen, sulphur, or oxygen, link to form a ring structure of 4 to 7 ring members.
  • R a -R b as used herein, either with regard to substituents present on a carbocyclic or heterocyclic moiety, or with regard to other substituents present at other locations on the compounds of the formula (I), includes inter alia compounds wherein R a is selected from a bond, O, CO, OC(O), SC(O), NR 0 C(O), OC(S), SC(S), NR 0 C(S), OC(NR 0 ), SC(NR 0 ), NR 0 C(NR 0 ), C(O)O, C(O)S, C(O)NR 0 , C(S)O, C(S)S, C(S) NR 0 , C(NR°)0, C(NR C )S, C(NR°)NR°, OC(O)O, SC(O)O, NR 0 C(O)O, OC(S)O, SC(O)O, NR 0 C(O)O, OC(S)
  • R b can be hydrogen or it can be a group selected from carbocyclic and heterocyclic groups having from 3 to 12 ring members (typically 3 to 10 and more usually from 5 to 10), and a C 1-8 hydrocarbyl group optionally substituted as hereinbefore defined. Examples of hydrocarbyl, carbocyclic and heterocyclic groups are as set out above.
  • R a and R b together form a hydrocarbyloxy group.
  • Preferred hydrocarbyloxy groups include saturated hydrocarbyloxy such as alkoxy (e.g. C 1-6 alkoxy, more usually C 1-4 alkoxy such as ethoxy and methoxy, particularly methoxy), cycloalkoxy (e.g. C 3-6 cycloalkoxy such as cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy) and cycloalkyalkoxy (e.g. C 3-6 cycloalkyl-Ci- 2 alkoxy such as cyclopropylmethoxy).
  • alkoxy e.g. C 1-6 alkoxy, more usually C 1-4 alkoxy such as ethoxy and methoxy, particularly methoxy
  • cycloalkoxy e.g. C 3-6 cycloalkoxy such as cyclopropyloxy, cyclobutyloxy,
  • the hydrocarbyloxy groups can be substituted by various substituents as defined herein.
  • the alkoxy groups can be substituted by halogen (e.g. as in difluoromethoxy and trifluoromethoxy), hydroxy (e.g. as in hydroxyethoxy), C 1-2 alkoxy (e.g. as in methoxyethoxy), hydroxy-Ct-2 alkyl (as in hydroxyethoxyethoxy) or a cyclic group (e.g. a cycloalkyl group or non-aromatic heterocyclic group as hereinbefore defined).
  • halogen e.g. as in difluoromethoxy and trifluoromethoxy
  • hydroxy e.g. as in hydroxyethoxy
  • C 1-2 alkoxy e.g. as in methoxyethoxy
  • hydroxy-Ct-2 alkyl e.g. a cycloalkyl group or non-aromatic heterocyclic group as hereinbefore defined
  • alkoxy groups bearing a non-aromatic heterocyclic group as a substituent are those in which the heterocyclic group is a saturated cyclic amine such as morpholine, piperidine, pyrrolidine, piperazine, C 1-4 -alkyl-piperazines, C 3-7 -cycloalkyl-piperazines, tetrahydropyran or tetrahydrofuran and the alkoxy group is a C 1-4 alkoxy group, more typically a C 1-3 alkoxy group such as methoxy, ethoxy or n- propoxy.
  • the heterocyclic group is a saturated cyclic amine such as morpholine, piperidine, pyrrolidine, piperazine, C 1-4 -alkyl-piperazines, C 3-7 -cycloalkyl-piperazines, tetrahydropyran or tetrahydrofuran
  • the alkoxy group is a C 1-4 alkoxy group, more typically a C
  • Alkoxy groups may be substituted by, for example, a monocyclic group such as pyrrolidine, piperidine, morpholine and piperazine and N-substituted derivatives thereof such as N-benzyl, N-CM acyl and N-C 1-4 alkoxycarbonyl.
  • a monocyclic group such as pyrrolidine, piperidine, morpholine and piperazine and N-substituted derivatives thereof such as N-benzyl, N-CM acyl and N-C 1-4 alkoxycarbonyl.
  • Particular examples include pyrrolidinoethoxy, piperidinoethoxy and piperazinoethoxy.
  • hydrocarbyl groups R a -R b are as hereinbefore defined.
  • the hydrocarbyl groups may be saturated groups such as cycloalkyl and alkyl and particular examples of such groups include methyl, ethyl and cyclopropyl.
  • the hydrocarbyl (e.g. alkyl) groups can be substituted by various groups and atoms as defined herein.
  • substituted alkyl groups include alkyl groups substituted by one or more halogen atoms such as fluorine and chlorine (particular examples including bromoethyl, chloroethyl, difluoromethyl, 2,2,2- trifluoroethyl and perfluoroalkyl groups such as trifluoromethyl), or hydroxy (e.g. hydroxymethyl and hydroxyethyl), C 1-8 acyloxy (e.g. acetoxymethyl and benzyloxymethyl), amino and mono- and dialkylamino (e.g.
  • halogen atoms such as fluorine and chlorine
  • hydroxy e.g. hydroxymethyl and hydroxyethyl
  • C 1-8 acyloxy e.g. acetoxymethyl and benzyloxymethyl
  • amino and mono- and dialkylamino e.g.
  • alkoxy e.g. C 1-2 alkoxy such as methoxy - as in methoxyethyl
  • cyclic groups such as cycloalkyl groups, aryl groups, heteroaryl groups and non- aromatic heterocyclic groups as hereinbefore defined.
  • alkyl groups substituted by a cyclic group are those wherein the cyclic group is a saturated cyclic amine such as morpholine, piperidine, pyrrolidine, piperazine, C ⁇ -alkyl-piperazines, C 3 .
  • alkyl group is a C 1-4 alkyl group, more typically a C 1 . 3 alkyl group such as methyl, ethyl or n-propyl.
  • alkyl groups substituted by a cyclic group include pyrrolidinomethyl, pyrrolidinopropyl, morpholinomethyl, morpholinoethyl, morpholinopropyl, piperidinylmethyl, piperazinomethyl and N- substituted forms thereof as defined herein.
  • alkyl groups substituted by aryl groups and heteroaryl groups include benzyl, phenethyl and pyridylmethyl groups.
  • R b can be, for example, hydrogen or an optionally substituted C 1-8 hydrocarbyl group, or a carbocyclic or heterocyclic group.
  • R a -R b where R a is SO 2 NR 0 include aminosulphonyl, C 1-4 alkylammosulphonyl and di-C 1-4 alkylaminosulphonyl groups, and sulphonamides formed from a cyclic amino group such as piperidine, morpholine, pyrrolidine, or an optionally N-substituted piperazine such as N-methyl piperazine.
  • R a -R b where R a is SO 2 examples include alkylsulphonyl, heteroarylsulphonyl and arylsulphonyl groups, particularly monocyclic aryl and heteroaryl sulphonyl groups. Particular examples include methylsulphonyl, phenylsulphonyl and toluenesulphonyl.
  • R b can be, for example, hydrogen or an optionally substituted C 1-8 hydrocarbyl group, or a carbocyclic or heterocyclic group.
  • R a -R b where R a is NR 0 include amino, C 1-4 alkylamino (e.g. methylamino, ethylamino, propylamino, isopropylamino, fert-butylamino), di-C 1-4 alkylamino (e.g. dimethylamino and diethylamino) and cycloalkylamino (e.g. cyclopropylamino, cyclopentylamino and cyclohexylamino) .
  • C 1-4 alkylamino e.g. methylamino, ethylamino, propylamino, isopropylamino, fert-butylamino
  • di-C 1-4 alkylamino e.g. dimethyl
  • Y 1 and Y 2 are both N + -O " or one of Y 1 and Y 2 is N and the other is N + -O-. In one embodiment, Y 1 and Y 2 are both N + -O " .
  • one of Y 1 and Y 2 is N and the other is N + -O ' .
  • R 1 and R 2 are the same or different and each is hydrogen or a substituent R 6 . More particularly, R 1 and R 2 are the same or different and each is hydrogen; halogen; trifluoromethyl; cyano; nitro; or a group R al -R bl ; wherein
  • R al is a bond, O, CO, X 1 C(X 2 ), C(X ⁇ X 1 , X 1 C(X ⁇ X 1 , S 5 SO, SO 2 , SO 2 NR C or NR 0 SO 2 ;
  • R bl is:
  • a Cw saturated hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy; oxo; halogen; cyano; nitro; carboxy; and carbocyclic and heterocyclic groups having from 3 to 6 ring members optionally substituted by one or more substituents selected from halogen, cyano, trifluoromethyl, trifluoromethoxy, difluoromethoxy, C 1-4 alkyl, C 1-4 alkylsulphonyl, C 1-4 acylamino ; wherein one or more carbon atoms of the C 1-6 saturated hydrocarbyl group may optionally be replaced by O, S, SO, SO 2 , NR 0 , X 1 C(X 2 ), C(X ⁇ X 1 Or X 1 C(X ⁇ X 1 ;
  • R° is R b , hydrogen or C 1-4 hydrocarbyl;
  • X 1 is O, S or NR 0 ; and
  • R 1 and R 2 can be same or different where each is hydrogen; halogen; ttrriifflluuoorrooimethyl; cyano; or a group R a2 -R b2 ; wherein
  • R a2 is a bond, CO, C(X ⁇ X 1 , SO, SO 2 , SO 2 NR 0 ;
  • R b2 is hydrogen or a C 1-6 saturated hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy; oxo; halogen; cyano; nitro; carboxy; wherein one or more carbon atoms of the C 1-6 saturated hydrocarbyl group may optionally be replaced by O, S 5 SO, SO 2 , X 1 C(X 2 ), C(X ⁇ X 1 or X 1 C(X ⁇ X 1 ;
  • R° is R b , hydrogen or C 1-4 hydrocarbyl
  • R 1 and R 2 are hydrogen or an electron withdrawing group (EWG).
  • EWG electron withdrawing group
  • R 1 and R 2 are the same or different and each is hydrogen, chlorine, fluorine, bromine, cyano, trifluoromethyl, trifluoromethoxy, difluoromethoxy, carbamoyl, mono- or di-C ⁇ alkylcarbamoyl, C 1-4 acyl, HuOrO-C 1-4 acyl or C 1-4 alkoxycarbonyl.
  • R 1 and R 2 are hydrogen, chlorine, fluorine, cyano, carbamoyl and trifluoromethyl.
  • More particular examples are hydrogen, chlorine and fluorine.
  • R 1 and R 2 may be attached to any of of the carbon atom in the benzene ring of the quinoxaline group.
  • R 1 or R 2 are each other than hydrogen, it is preferred that they are located at the 6- and/or 7-positions of the quinoxaline ring, the 6- and 7- positions being as shown below.
  • R 1 and R 2 are selected so that the one electron reduction potential E(I) of the quinoxaline group is between -300 mV and -510 mV, and more preferably from -450 mV to -510 mV.
  • R is a cyano group located at the 6-position of the quinoxaline ring and R 1 is hydrogen or a substituent as defined herein.
  • R 2 is a cyano group located at the 7- position of the quinoxaline ring and R 1 is hydrogen or a substituent as defined herein.
  • Preferred quinoxaline moieties include the groups A6 and A7.
  • Q is N.
  • Q is N + -O " .
  • G The moiety G is CH 2 , O 5 NH, NHCO or CONH.
  • G is CH 2 , O or NH.
  • G is O.
  • A is a group (CH 2 ) n where n is 1 to 4 provided that when G is O or NH, n is at least 2.
  • n is 2 or 3. hi one particular group of compounds, n is 3 and hence the group (CH 2 ) n is a propylene group.
  • R 3 and R 4 are the same or different and each is hydrogen or C 1-4 alkyl; or R 3 and R 4 together with the nitrogen atom to which they are attached form an azetidine, pyrrolidine, piperidine, piperazine, N-methylpiperazine or morpholine group.
  • R 3 and R 4 are C 1-4 alkyl
  • preferred alkyl groups are C 1-3 alkyl groups and C 1-2 alkyl groups.
  • Each of V 2 and V 3 can be nitrogen or a group CR 5 , provided that no more than two of V 2 , V 3 and V 4 are nitrogen.
  • V 2 is CH or a group CR 6a , where R 6a is:
  • C 1-4 alkyl optionally substituted by one or more fluorine atoms, hydroxy, C 1-2 alkoxy, cyano, amino or mono- or di-C 1-4 alkylamino;
  • V 3 is CH or a group CR 6 as hereinbefore defined.
  • V 2 are CH and CR 6a where R 6a is :
  • C 1-3 alkyl optionally substituted by one or more fluorine atoms, hydroxy, C 1-2 alkoxy, cyano or amino or mono- or di-C 1-2 alkylamino;
  • V 2 is CH or C-Cl.
  • V 3 are CH and CR 6b where R 6b is halogen; hydroxy; trifluoromethyl; cyano; amino; mono- or di-C 1-4 hydrocarbylamino; a carbocyclic group of 3 to 6 ring members or a heterocyclic group of 5 to 6 ring members, the carbocyclic and heterocyclic groups being optionally substituted by one or more substituents R 7a ; or a group R a -R b ;
  • R a is a bond, O, CO 5 X 1 C(X 2 ), S, SO, SO 2 , NR 0 , SO 2 NR 0
  • R b is: • hydrogen; • a carbocyclic group of 3 to 6 ring members or a heterocyclic group of 5 to 6 ring members being optionally substituted by one or more substituents R 7a ;
  • R 8a is the same as R 6b except that any carbocyclic or heterocyclic groups constituting or forming part of R 8a may not bear a substituent containing or consisting of a carbocyclic or heterocyclic group but may optionally bear one or more substituents selected from
  • ⁇ C 1-4 alkyl optionally substituted by one or more fluorine atoms, hydroxy, Ci -2 alkoxy, cyano, amino or mono- or di-C 1-4 alkylamino; ⁇ Ci -4 alkoxy optionally substituted by one or more fluorine atoms or C 1-2 alkoxy;
  • One preferred group is group Bl.
  • R 1 , R 2 , R 3 , R 4 , R 5 , Q and A are as hereinbefore defined.
  • R 9 is hydrogen or a substituent selected from: ⁇ halogen
  • C 1-4 alkyl optionally substituted by one or more fluorine atoms, hydroxy, C 1-2 alkoxy, cyano, amino or mono- or di-C 1-4 alkylamino;
  • R 10 is hydrogen or a substituent selected from halogen; hydroxy; trifluoromethyl; cyano; amino; mono- or di-C 1-4 hydrocarbylamino; a carbocyclic group of 3 to 6 ring members or a heterocyclic group of 5 to 6 ring members, the carbocyclic and heterocyclic groups being optionally substituted by one or more substituents R 7a ; or a group R a -R b ;
  • R a is a bond, O, CO, X 1 C(X 2 ), C(X ⁇ X 1 , X 1 C(X 2 JX. 1 , S, SO, SO 2 , NR C , SO 2 NR 0 Or NR 0 SO 2 ;
  • R b is:
  • Preferred compounds of the present invention are those having a one electron reduction potential E(I) of between -300 mV and -510 mV, and more preferably from -450 mV to -510 mV.
  • E(I) can be measured by a number of techniques including pulse radiolysis, see for example (i) M. P Hay et al. J. Med. Chem., 2003, 46:169-182 (ii) E. J Land et al., Arch Biochem Biophys. 1983 Aug; 225(1):116-21; (iii) Patel and Willson (K B Patel and R L Willson. Journal of the Chemical Society, Faraday Transactions 1, 1973, 69, 814-825); (iv) D Meisel and P Neta.
  • the various functional groups and substituents making up the compounds of the formula (I) are typically chosen such that the molecular weight of the compound of the formula (I) does not exceed 1000. More usually, the molecular weight of the compound will be less than 750, for example less than 700, or less than 650, or less than 600, or less than 550. More preferably, the molecular weight is less than 525 and, for example, is 500 or less.
  • a reference to a compound of the formula (1) and sub-groups thereof also includes ionic forms, salts, solvates, isomers, tautomers, prodrugs, isotopes and protected forms thereof, for example, as discussed below.
  • salts for example acid addition salts or, in certain cases salts of organic and inorganic bases such as phenolate, carboxylate, sulphonate and phosphate salts. All such salts are within the scope of this invention, and references to compounds of the formula (1) include the salt forms of the compounds.
  • the salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods such as methods described in Pharmaceutical Salts: Properties, Selection, and Use, P. Heinrich Stahl (Editor), Camille G. Wermuth (Editor), ISBN: 3-90639-026-8, Hardcover, 388 pages, August 2002.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used.
  • Acid addition salts may be formed with a wide variety of acids, both inorganic and organic.
  • acid addition salts include salts formed with an acid selected from the group consisting of acetic, 2,2-dichloroacetic, adipic, alginic, ascorbic (e.g.
  • a salt may be formed with a suitable cation.
  • suitable inorganic cations include, but are not limited to, alkali metal ions such as Na and K + , alkaline earth metal cations such as Ca 2+ and Mg 2+ , and other cations such as Al 3+ .
  • suitable organic cations include, but are not limited to, ammonium ion (i.e., NH 4 + ) and substituted ammonium ions (e.g., NH 3 R + , NH 2 R 2 + , NHR 3 + , NR 4 + ).
  • Examples of some suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine.
  • An example of a common quaternary ammonium ion is N(CH 3 ) 4 + .
  • the compounds of the formula (1) contain an amine function
  • these may form quaternary ammonium salts, for example by reaction with an alkylating agent according to methods well known to the skilled person.
  • Such quaternary ammonium compounds are within the scope of formula (1).
  • the salt forms of the compounds of the invention are typically pharmaceutically acceptable salts, and examples of pharmaceutically acceptable salts are discussed in Berge et ah, 1977, "Pharmaceutically Acceptable Salts," J. Pharm. ScL, Vol. 66, pp. 1- 19. However, salts that are not pharmaceutically acceptable may also be prepared as intermediate forms which may then be converted into pharmaceutically acceptable salts. Such non-pharmaceutically acceptable salts forms, which may be useful, for example, in the purification or separation of the compounds of the invention, also form part of the invention.
  • tautomeric forms include, for example, keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, and nitro/aci-nitro.
  • keto enol enolate as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, and nitro/aci-nitro.
  • references to compounds of the formula (I) include all optical isomeric forms thereof (e.g. enantiomers, epimers and diastereoisomers), either as individual optical isomers, or mixtures (e.g. racemic mixtures) or two or more optical isomers, unless the context requires otherwise.
  • optical isomers may be characterised and identified by their optical activity (i.e. as + and - isomers, or d and / isomers) or they may be characterised in terms of their absolute stereochemistry using the "R and S" nomenclature developed by Cahn, Ingold and Prelog, see Advanced Organic Chemistry by Jerry March, 4 th Edition, John Wiley & Sons, New York, 1992, pages 109-114, and see also Cahn, Ingold & Prelog, Angew. Chem. Int. Ed. Engl, 1966, 5, 385-415.
  • Optical isomers can be separated by a number of techniques including chiral chromatography (chromatography on a chiral support) and such techniques are well known to the person skilled in the art.
  • optical isomers can be separated by forming diastereoisomeric salts with chiral acids such as (+)-tartaric acid, (-)- pyroglutamic acid, (-)-di-toluoyl-L-tartaric acid, (+)-mandelic acid, (-)-malic acid, and (-)-camphorsulphonic, separating the diastereoisomers by preferential crystallisation, and then dissociating the salts to give the individual enantiomer of the free base.
  • chiral acids such as (+)-tartaric acid, (-)- pyroglutamic acid, (-)-di-toluoyl-L-tartaric acid, (+)-mandelic acid, (-)-malic acid, and (-)-camphorsulphonic
  • compositions containing a compound of the formula (I) having one or more chiral centres wherein at least 55% (e.g. at least 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%) of the compound of the formula (I) is present as a single optical isomer (e.g.
  • 99% or more (e.g. substantially all) of the total amount of the compound of the formula (1) may be present as a single optical isomer (e.g. enantiomer or diastereoisomer).
  • the compounds of the invention include compounds with one or more isotopic substitutions, and a reference to a particular element includes within its scope all isotopes of the element.
  • a reference to hydrogen includes within its scope 1 H, 2 H (D), and 3 H (T).
  • references to carbon and oxygen include within their scope respectively 12 C, 13 C and 14 C and 16 O and 18 O.
  • the isotopes may be radioactive or non-radioactive.
  • the compounds contain no radioactive isotopes. Such compounds are preferred for therapeutic use.
  • the compound may contain one or more radioisotopes. Compounds containing such radioisotopes may be useful in a diagnostic context.
  • Also encompassed by formula (1) are any polymorphic forms of the compounds, solvates (e.g. hydrates), complexes (e.g. inclusion complexes or clathrates with compounds such as cyclodextrins, or complexes with metals) of the compounds, and pro-drugs of the compounds.
  • prodrugs is meant for example any compound that is converted in vivo into a biologically active compound of the formula (1).
  • C 1-7 alkyl e.g., -Me, -Et, -nPr, -iPr, -nBu, -sBu, -iBu, -tBu;
  • acyloxymethyl e.g., acyloxymethyl; acyloxyethyl; pivaloyloxymethyl; acetoxymethyl;
  • prodrugs are activated enzymatically to yield the active compound, or a compound which, upon further chemical reaction, yields the active compound (for example, as in ADEPT 5 GDEPT, LIDEPT, etc.).
  • the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative.
  • the compounds of the formula (1) wherein both Y 1 and Y 2 are N- oxide groups will be reduced to the mono-N-oxides in hypoxic tumour cells and that the reduction process will result in damage to the DNA of the tumour cell and therefore cell death.
  • the mono-N-oxides may undergo further reduction to the parent heterocycle, thereby (potentially) causing further DNA damage in the hypoxic tumour cell and consequent cell death.
  • Both the mono-N-oxides and the parent heterocycles have Chk-1 inhibiting activity which prevents the checkpoint arrests at, for example, the G2 checkpoint and hence stops the normal repairing processes from taking place.
  • the compounds of the invention are believed to act against hypoxic cancer cells in two ways. Firstly, they are reduced in hypoxic conditions and the act of reduction results in damage to the DNA of the tumour cell. Secondly, the reduced products block the normal cell repair processes thereby enhancing the cytotoxic effect of the N-oxides.
  • the compounds of the invention will be useful in treating a range of proliferative diseases and in particular solid tumours containing a significant mass of hypoxic cells.
  • the compounds of the invention will also act in a synergistic or additive manner with other chemotherapeutic agents and cancer treatments such as radiotherapy against a wide spectrum of proliferative disorders.
  • proliferative disorders include, but are not limited to carcinomas, for example carcinomas of the bladder, breast, colon, kidney, epidermis, liver, lung, oesophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, gastrointestinal system, or skin, thyroid follicular cancer; tumours of mesenchymal origin, for example fibrosarcoma or habdomyosarcoma; tumours of the central or peripheral nervous system, for example astrocytoma, neuroblastoma, glioma or schwannoma; melanoma; seminoma; teratocarcinoma; osteosarcoma; xeroderma pigmentosum; keratoctanthoma; thyroid follicular cancer; or Kaposi's sarcoma.
  • carcinomas for example carcinomas of the bladder, breast, colon, kidney, epidermis, liver, lung, oesophagus, gall bladder, ovary, pancrea
  • the Chk-1 inhibitor compounds of the invention may be used in combination with DNA-damaging anti-cancer drugs and/or radiation therapy to treat subjects with multidrug resistant cancers.
  • a cancer is considered to be resistant to a drug when it resumes a normal rate of tumour growth while undergoing treatment with the drug after the tumour had initially responded to the drug.
  • a tumour is considered to "respond to a drug" when it exhibits a decrease in tumor mass or a decrease in the rate of tumour growth.
  • Chkl inhibitors of the invention may be useful in treating tumours in which mutations (e.g. in p53) have led to the Gl/S DNA damage checkpoint being lost (see the introductory section of this application)
  • references to Formula (1) also include all sub-groups and examples therof as
  • the compounds of formula (1) can be prepared by the reaction of a compound of formula (10) :
  • V 2 , V 3 , V 4 , G, A, Q, R 1 , R 2 , R 3 , and R 4 are as hereinbefore defined, with an oxidising agent capable of oxidizing quinoxaline ring nitrogens to atom to N-oxides.
  • oxiding agents include:
  • peroxycarboxylic acids such as weto-chloroperbenzoic acid (mCPBA), peracetic acid/sodum acetate and diperoxymaleic acid (see Organic and
  • peroxysulphuric acid Caro's acid
  • salts thereof such as potassium peroxymonosulphate (e.g. Oxone ® /dimethyldioxirane - J. Org. Chem., 1977,
  • Azides of the formula (12) can be prepared from the corresponding carboxylic acid of the formula (13):
  • reaction by reaction with diphenylphosphorylazide in a polar non-protic solvent such as tetrahydrofuran (THF) in the presence of a non-interfering base such as triethylamine.
  • a polar non-protic solvent such as tetrahydrofuran (THF)
  • THF tetrahydrofuran
  • a non-interfering base such as triethylamine
  • the azide can be made by forming an acid chloride of the carboxylic acid, and reacting the acid chloride with sodium azide.
  • compounds of the formulae (13) can be obtained commercially or can be made using standard methods well known to the skilled chemist.
  • compounds of the formula (13) can be prepared by the methods described in (i) WO 2005/019168; (ii) CA 2376024, (iii) J. Med. Chem., 1981, 24, 93-101; (iv) J. Med. Chem., 1970, 13(5), 1005- 8; and (v) EP 0720988.
  • reaction is typically carried out in a polar solvent or a mixture of a polar solvent (e.g. isopropanol) and a non-polar solvent (e.g. an aromatic hydrocarbon such as toluene), in the presence of a strong base such as an alkali metal alkoxide (e.g. sodium methoxide) in order to generate a phenolate anion.
  • a polar solvent e.g. isopropanol
  • non-polar solvent e.g. an aromatic hydrocarbon such as toluene
  • a strong base such as an alkali metal alkoxide (e.g. sodium methoxide) in order to generate a phenolate anion.
  • the reaction mixture may be heated, e.g. to the reflux temperature of the solvent.
  • the coupling reaction between the carboxylic acid (16) and the amine (15) is preferably carried out in the presence of a reagent of the type commonly used in the formation of peptide linkages.
  • a reagent of the type commonly used in the formation of peptide linkages examples include 1,3-dicyclohexylcarbodiimide (DCC) (Sheehan et a ⁇ , J. Amer. Chem Soc, 1955, 77, 1067), l-ethyl-3-(3'- dimethylaminopropyl)-carbodiimide (referred to herein either as EDC or EDAC but also known in the art as EDCI and WSCDI) (Sheehan et al, J. Org.
  • uronium-based coupling agents such as 0-(7-azabenzotriazol-l-yl)-N,-V,iV ') ) ./V'- tetramethyluronium hexafluorophosphate (HATU) and phosphonium-based coupling agents such as l-benzo-triazolyloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate (PyBOP) (Castro et al, Tetrahedron Letters, 1990, 3_I, 205).
  • Carbodiimide-based coupling agents are advantageously used in combination with 1- hydroxy-7-azabenzotriazole (HOAt) (L.
  • Preferred coupling reagents include EDC (EDAC) and DCC in combination with HOAt or HOBt.
  • the coupling reaction is typically carried out in a non-aqueous, non-protic solvent such as acetonitrile, dioxan, dimethylsulphoxide, dichloromethane, dimethylformamide or N-methylpyrrolidine, or in an aqueous solvent optionally together with one or more miscible co-solvents.
  • a non-aqueous, non-protic solvent such as acetonitrile, dioxan, dimethylsulphoxide, dichloromethane, dimethylformamide or N-methylpyrrolidine
  • an aqueous solvent optionally together with one or more miscible co-solvents.
  • the reaction can be carried out at room temperature or, where the reactants are less reactive (for example in the case of electron-poor anilines bearing electron withdrawing groups such as sulphonamide groups) at an appropriately elevated temperature.
  • the reaction may be carried out in the presence of a non-interfering base, for example a tertiary amine such as triethyl
  • a reactive derivative of the carboxylic acid e.g. an anhydride or acid chloride
  • Reaction with a reactive derivative such an anhydride is typically accomplished by stirring the amine and anhydride at room temperature in the presence of a base such as pyridine.
  • the chloro-amide (17) is then converted to the aminoalkylamide (18) by reaction with a secondary amine R 4 R 3 NH, typically at an elevated temperature in a solvent such as chloroform, dichloromethane or dimethylformamide, or more typically acetonitrile in the presence of an alkali metal carbonate base such as potassium carbonate.
  • a secondary amine R 4 R 3 NH typically at an elevated temperature in a solvent such as chloroform, dichloromethane or dimethylformamide, or more typically acetonitrile in the presence of an alkali metal carbonate base such as potassium carbonate.
  • the aminoalkylamide (18) is then deprotected (e.g. in the case of boc by treatment with an acid) and the amine reacted with an azide of the formula (12) as described above to give a compound of the formula (10).
  • the isocyanate (23) typically by heating (22) and (23) together to form the urea.
  • the isocyanate (23) can be prepared from an amine of formula (11) by reaction with phosgene in a non-protic solvent such as toluene.
  • Quinoxaline amines of the formula (22) can be prepared by methods described in US 2650221, GB 693353 and in J. Org. Chem., 1971, 36(8), 1158-60.
  • ammonia or ammonium hydroxide for example as described in J. Med. Chem., 1968, 946-949 or JP 60097964.
  • reaction can be reacted with an amine of the formula (11).
  • the reaction is typically effected by heating the two compounds together in a suitable non-reactive solvent.
  • the carbamate (20) can be prepared from the quinoxaline amine (22) by reaction with phenylchloroformate .
  • the N-oxide is formed in the final step in the reaction sequence after urea bond formation has taken place.
  • N- oxidation can be effected before urea bond formation. This may be achieved by oxidising the quinoxaline amine (22) (e.g. with a peracetic acid/sodium acetate mixture) to give an N 5 N' -dioxide of the formula (25):
  • one compound of the formula (1), or a protected derivative thereof, can be converted into another compound of the formula (1) by methods well known to the skilled person.
  • Examples of synthetic procedures for converting one functional group into another functional group are set out in standard texts such as Advanced Organic Chemistry, by Jerry March, 4 th edition, 119, Wiley Interscience, New York; Fiesers' Reagents for Organic Synthesis, Volumes 1-17, John Wiley, edited by Mary Fieser (ISBN: 0-471-58283-2); and Organic Syntheses, Volumes 1-8, John Wiley, edited by Jeremiah P. Freeman (ISBN: 0-471-31192-8)).
  • Cmpounds made by the foregoing methods may be isolated and purified by any of a variety of methods well known to those skilled in the art and examples of such methods include recrystallisation and chromatographic techniques such as column chromatography (e.g. flash chromatography) and HPLC.
  • the active compound While it is possible for the active compound to be administered alone, it is preferable to present it as a pharmaceutical composition (e.g. formulation) comprising at least one active compound of the invention together with a pharmaceutically acceptable carrier, and optionally one or more additional excipients.
  • a pharmaceutical composition e.g. formulation
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the formula (1) and a pharmaceutically acceptable carrier.
  • compositions can be in any form suitable for oral, parenteral, topical, intranasal, ophthalmic, otic, rectal, intra-vaginal, or transdermal administration.
  • compositions are intended for parenteral administration, they can be formulated for intravenous, intramuscular, intraperitoneal, subcutaneous administration or for direct delivery into a target organ or tissue by injection, infusion or other means of delivery.
  • the delivery can be by bolus injection, short term infusion or longer term infusion and can be via passive delivery or through the utilisation of a suitable infusion pump.
  • compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, co-solvents, organic solvent mixtures, cyclodextrin complexation agents, emulsifying agents (for forming and stabilizing emulsion formulations), liposome components for forming liposomes, gellable polymers for forming polymeric gels, lyophilisation protectants and combinations of agents for, inter alia, stabilising the active ingredient in a soluble form and rendering the formulation isotonic with the blood of the intended recipient.
  • aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, co-solvents, organic solvent mixtures, cyclodextrin complexation agents, emulsifying agents (for forming and stabilizing emulsion formulations), liposome components for forming liposomes, gellable polymers for forming polymeric gels,
  • compositions for parenteral administration may also take the form of aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents (R. G. Strickly, Solubilizing Excipients in oral and injectable formulations, Pharmaceutical Research, VoI 21(2) 2004, p 201-230).
  • a drug molecule that is ionizable can be solubilized to the desired concentration by pH adjustment if the drug's pK a is sufficiently away from the formulation pH value.
  • the acceptable range is pH 2-12 for intravenous and intramuscular administration, but subcutaneously the range is pH 2.7-9.0.
  • the solution pH is controlled by either the salt form of the drug, strong acids/bases such as hydrochloric acid or sodium hydroxide, or by solutions of buffers which include but are not limited to buffering solutions formed from glycine, citrate, acetate, maleate, succinate, histidine, phosphate, tris(hydroxymethyl)- aminomethane (TRIS), or carbonate.
  • the combination of an aqueous solution and a water-soluble organic solvent/surfactant is often used in injectable formulations.
  • the water-soluble organic solvents and surfactants used in injectable formulations include but are not limited to propylene glycol, ethanol, polyethylene glycol 300, polyethylene glycol 400, glycerin, dimethylacetamide (DMA), N-methyl-2-pyrrolidone (NMP; Pharmasolve), dimethylsulphoxide (DMSO), Solutol HS 15, Cremophor EL, Cremophor RH 60, and polysorbate 80.
  • Such formulations can usually be, but are not always, diluted prior to injection.
  • Propylene glycol, PEG 300, ethanol, Cremophor EL, Cremophor RH 60, and polysorbate 80 are the entirely organic water-miscible solvents and surfactants used in commercially available injectable formulations and can be used in combinations with each other.
  • the resulting organic formulations are usually diluted at least 2-fold prior to IV bolus or IV infusion.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • sterile liquid carrier for example water for injections
  • the pharmaceutical formulation can be prepared by lyophilising a compound of Formula (1) or acid addition salt thereof.
  • Lyophilisation refers to the procedure of freeze-drying a composition. Freeze-drying and lyophilisation are therefore used herein as synonyms.
  • a typical process is to solubilise the compound and the resulting formulation is clarified, sterile filtered and aseptically transferred to containers appropriate for lyophilisation (e.g. vials). In the case of vials, they are partially stoppered with lyo-stoppers.
  • the formulation can be cooled to freezing and subjected to lyophilisation under standard conditions and then hermetically capped forming a stable, dry lyophile formulation.
  • the composition will typically have a low residual water content, e.g. less than 5% e.g. less than 1% by weight based on weight of the lyophile.
  • the lyophilisation formulation may contain other excipients for example, thickening agents, dispersing agents, buffers, antioxidants, preservatives, and tonicity adjusters.
  • Typical buffers include phosphate, acetate, citrate and glycine.
  • antioxidants include ascorbic acid, sodium bisulphite, sodium metabisulphite, monothioglycerol, thiourea, butylated hydroxytoluene, butylated hydroxyl anisole, and ethylenedianiinetetraacetic acid salts.
  • Preservatives may include benzoic acid and its salts, sorbic acid and its salts, alkyl esters of j> ⁇ r ⁇ -hydroxybenzoic acid, phenol, chlorobutanol, benzyl alcohol, thimerosal, benzalkonium chloride and cetylpyridinium chloride.
  • the buffers mentioned previously, as well as dextrose and sodium chloride, can be used for tonicity adjustment if necessary.
  • Bulking agents are generally used in lyophilisation technology for facilitating the process and/or providing bulk and/or mechanical integrity to the lyophilized cake.
  • Bulking agent means a freely water soluble, solid particulate diluent that when co- lyophilised with the compound or salt thereof, provides a physically stable lyophilized cake, a more optimal freeze-drying process and rapid and complete reconstitution.
  • the bulking agent may also be utilised to make the solution isotonic.
  • the water-soluble bulking agent can be any of the pharmaceutically acceptable inert solid materials typically used for lyophilisation.
  • Such bulking agents include, for example, sugars such as glucose, maltose, sucrose, and lactose; polyalcohols such as sorbitol or mannitol; amino acids such as glycine; polymers such as polyvinylpyrrolidine; and polysaccharides such as dextran.
  • the ratio of the weight of the bulking agent to the weight of active compound is typically within the range from about 1 to about 5, for example of about 1 to about 3, e.g. in the range of about 1 to 2.
  • dosage forms may be via filtration or by autoclaving of the vials and their contents at appropriate stages of the formulation process.
  • the supplied formulation may require further dilution or preparation before delivery for example dilution into suitable sterile infusion packs.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
  • the pharmaceutical composition is in a form suitable for i.v. administration, for example by injection or infusion.
  • the pharmaceutical composition is in a form suitable for sub-cutaneous (s.c.) administration.
  • Pharmaceutical dosage forms suitable for oral administration include tablets, capsules, caplets, pills, lozenges, syrups, solutions, powders, granules, elixirs and suspensions, sublingual tablets, wafers or patches and buccal patches.
  • compositions containing compounds of the formula (1) can be formulated in accordance with known techniques, see for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.
  • tablet compositions can contain a unit dosage of active compound together with an inert diluent or carrier such as a sugar or sugar alcohol, eg; lactose, sucrose, sorbitol or mannitol; and/or a non-sugar derived diluent such as sodium carbonate, calcium phosphate, calcium carbonate, or a cellulose or derivative thereof such as methyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, and starches such as corn starch. Tablets may also contain such standard ingredients as binding and granulating agents such as polyvinylpyrrolidone, disintegrants (e.g.
  • swellable crosslinked polymers such as crosslinked carboxymethylcellulose
  • lubricating agents e.g. stearates
  • preservatives e.g. parabens
  • antioxidants e.g. BHT
  • buffering agents for example phosphate or citrate buffers
  • effervescent agents such as citrate/bicarbonate mixtures.
  • Capsule formulations may be of the hard gelatin or soft gelatin variety and can contain the active component in solid, semi-solid, or liquid form.
  • Gelatin capsules can be formed from animal gelatin or synthetic or plant derived equivalents thereof.
  • the solid dosage forms can be coated or un-coated, but typically have a coating, for example a protective film coating (e.g. a wax or varnish) or a release controlling coating.
  • a protective film coating e.g. a wax or varnish
  • the coating e.g. a Eudragit TM type polymer
  • the coating can be designed to release the active component at a desired location within the gastrointestinal tract.
  • the coating can be selected so as to degrade under certain pH conditions within the gastrointestinal tract, thereby selectively release the compound in the stomach or in the ileum or duodenum.
  • the drug can be presented in a solid matrix comprising a release controlling agent, for example a release delaying agent which may be adapted to selectively release the compound under conditions of varying acidity or alkalinity in the gastrointestinal tract.
  • a release controlling agent for example a release delaying agent which may be adapted to selectively release the compound under conditions of varying acidity or alkalinity in the gastrointestinal tract.
  • the matrix material or release retarding coating can take the form of an erodible polymer (e.g. a maleic anhydride polymer) which is substantially continuously eroded as the dosage form passes through the gastrointestinal tract.
  • the active compound can be formulated in a delivery system that provides osmotic control of the release of the compound. Osmotic release and other delayed release or sustained release formulations may be prepared in accordance with methods well known to those skilled in the art.
  • the pharmaceutical formulations may be presented to a patient in "patient packs" containing an entire course of treatment in a single package, usually a blister pack.
  • Patient packs have an advantage over traditional prescriptions, where a pharmacist divides a patient's supply of a pharmaceutical from a bulk supply, in that the patient always has access to the package insert contained in the patient pack, normally missing in patient prescriptions.
  • the inclusion of a package insert has been shown to improve patient compliance with the physician's instructions.
  • compositions for topical use include ointments, creams, sprays, patches, gels, liquid drops and inserts (for example intraocular inserts). Such compositions can be formulated in accordance with known methods.
  • compositions for parenteral administration are typically presented as sterile aqueous or oily solutions or fine suspensions, or may be provided in finely divided sterile powder form for making up extemporaneously with sterile water for injection.
  • formulations for rectal or intra-vaginal administration include pessaries and suppositories which may be, for example, formed from a shaped moldable or waxy material containing the active compound.
  • compositions for administration by inhalation may take the form of inhalable powder compositions or liquid or powder sprays, and can be administrated in standard form using powder inhaler devices or aerosol dispensing devices. Such devices are well known.
  • the powdered formulations typically comprise the active compound together with an inert solid powdered diluent such as lactose.
  • a formulation may contain from 1 nanogram to 2 grams of active ingredient, e.g. from 1 nanogram to 2 milligrams of active ingredient.
  • particular sub-ranges of compound are 0.1 milligrams to 2 grams of active ingredient (more usually from 10 milligrams to 1 gram, e.g. 50 milligrams to 500 milligrams), or 1 microgram to 20 milligrams (for example 1 microgram to 10 milligrams, e.g. 0.1 milligrams to 2 milligrams of active ingredient).
  • a unit dosage form may contain from 1 milligram to 2 grams, more typically 10 milligrams to 1 gram, for example 50 milligrams to 1 gram, e.g. 100 miligrams to 1 gram, of active compound.
  • the active compound will be administered to a patient in need thereof (for example a human or animal patient) in an amount sufficient to achieve the desired therapeutic effect.
  • the compounds of the formula (1) and sub-groups as defined herein will be useful either as sole chemotherapeutic agents or, more usally, in combination therapy with chemotherapeutic agents or radiation therapy in the prophylaxis or treatment of a range of proliferative disease states or conditions. Examples of such disease states and conditions are set out above.
  • chemotherapeutic agents that may be co-administered with the compounds of formula (I) include:
  • the compounds may be administered over a prolonged term to maintain beneficial therapeutic effects or may be administered for a short period only. Alternatively they may be administered in a pulsatile or continuous manner.
  • the compounds of the invention will be administered in an effective amount, i.e. an amount which is effective to bring about the desired therapeutic effect.
  • the "effective amount" can be a quantity of compound which, when administered together with a chemotherapeutic agent to a subject suffering from cancer, slows tumour growth, ameliorates the symptoms of the disease and/or increases longevity.
  • an effective amount of the Chk-1 inhibitor of the invention is the quantity in which a greater response is achieved when the Chk-1 inhibitor is co-administered with the DNA damaging anti-cancer drug and/or radiation therapy compared with when the DNA damaging anti-cancer drug and/or radiation therapy is administered alone.
  • an "effective amount" of the DNA damaging drug and/or an "effective" radiation dose are administered to the subject, which is a quantity in which anti-cancer effects are normally achieved.
  • Chk-1 inhibitors of the invention and the DNA damaging anti- cancer drug can be co-administered to the subject as part of the same pharmaceutical composition or, alternatively, as separate pharmaceutical compositions.
  • the Chk-1 inhibitor of the invention and the DNA-damaging anti-cancer drug (and/or radiation therapy) can be administered simultaneously or at different times, provided that the enhancing effect of theChk-1 inhibitor is retained.
  • Chk-1 inhibitor compound of the invention and the DNA damaging anti-cancer drug and radiation dose administered to the subject will depend on the type and severity of the disease or condition and on the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs. The skilled person will be able to determine appropriate dosages depending on these and other factors. Effective dosages for commonly used anti-cancer drugs and radiation therapy are well known to the skilled person.
  • the compounds are generally administered to a subject in need of such administration, for example a human or animal patient, preferably a human.
  • a typical daily dose of the compound of formula (1) can be in the range from 100 picograms to 100 milligrams per kilogram of body weight, more typically 5 nanograms to 25 milligrams per kilogram of bodyweight, and more usually 10 nanograms to 15 milligrams per kilogram (e.g. 10 nanograms to 10 milligrams, and more typically 1 microgram per kilogram to 20 milligrams per kilogram, for example 1 microgram to 10 milligrams per kilogram) per kilogram of bodyweight although higher or lower doses may be administered where required.
  • the compound can be administered on a daily basis or on a repeat basis every 2, or 3, or 4, or 5, or 6, or 7, or 10 or 14, or 21, or 28 days for example.
  • a patient will be given an infusion of a compound for periods of one hour daily for up to ten days in particular up to five days for one week, and the treatment repeated at a desired interval such as two to four weeks, in particular every three weeks.
  • a patient may be given an infusion of a compound for periods of one hour daily for 5 days and the treatment repeated every three weeks.
  • a patient is given an infusion over 30 minutes to 1 hour followed by maintenance infusions of variable duration, for example 1 to 5 hours, e.g. 3 hours.
  • a patient is given a continuous infusion for a period of 12 hours to 5 days, an in particular a continuous infusion of 24 hours to 72 hours.
  • the quantity of compound administered and the type of composition used will be commensurate with the nature of the disease or physiological condition being treated and will be at the discretion of the physician.
  • Mass Spectrometer Ionization mode Positive Negative Capillary Voltage: 3.2OkV -3.0OkV Cone Voltage: 30V -30V Source Temperature: HO 0 C 110 0 C Desolvation Temperature : 350 0 C 350°C Cone Gas Flow: 30 L/Hr 30 L/Hr Desolvation Gas Flow: 400 L/Hr 400 L/Hr Scan duration: 0.50 seconds 0.50 seconds InterScan delay: 0.20 seconds 0.20 seconds Mass range: SO to lOOO AMU 8O tO lOOO AMU
  • Step A Quinoxalin-2-ylamine (1.72 mmol) was dissolved in pyridine (10 ml) and a catalytic amount of DMAP was added followed by addition of 1.2 equivalents of phenylchloroformate. The reaction was stirred at room temperature for 2 hours. The solvent was removed by evaporation and purified by column chromatography eluting 30-50% ethyl acetate/hexanes.
  • Step B Quinoxalin-2-yl-carbarnic acid phenyl ester (170 mg) was dissolved in dioxane (20ml) and 1.0 equivalent of [3-(2-amino-4-chloro-phenoxy)-propyl]-carbamic acid tert-butyl ester was added and the reaction was heated to 100 0 C for 3 hours. The reaction mixture was concentrated and purified by column chromatography eluting 0- 60% ethyl acetate/hexanes.
  • Step C Hydrogen peroxide (170 ⁇ L; 30% w/v) and maleic anhydride (42 mg) were added to a solution of ⁇ 3-[4-chloro-2-(3-qumoxalin ⁇ 2-yl-ureido) ⁇ phenoxy]-propyl ⁇ - carbamic acid tert-butyl ester (200 mg) in acetic acid (4 ml). After standing overnight at 20° C, the mixture was poured on to ice-water and the precipitate was removed by filtration.
  • 2,6-Dichloroquinoxaline is reacted with ammonia under the conditions described in J. Med. Chem., 1968, 946-949 to give 2-amino-6-chloroquinoxaline.
  • 2-Amino-6- chloroquinoxaline in turn is treated with sodium cyanide in the presence of nickel (II) bromide under the conditions described in J. Org. Chem., 2003, 68, 9122-9125 to give the title compound.
  • Example 16B is oxidised using hydrogen peroxide under the conditions described in Example 1 Step C to give the title compounds as a mixture that can be separated by means of HPLC.
  • the starting material, 7-bromo-quinoxalin-2-ylamine can be prepared by the methods described in Zeszyty Naukowe Uniwersytetu Jagiellonskiego, Prace Chemiczne (1979), 24, 7-12 and Czasopismo Techniczne (Krakow) (1997), 94(3), 122-128).
  • the 2-amino- 7-bromoquinoxaline in turn is treated with sodium cyanide in the presence of nickel (II) bromide under the conditions described in J. Org. Chem., 2003, 68, 9122-9125 to give the title compound.
  • Example 17B is oxidised using hydrogen peroxide under the conditions described in Example 1 Step C to give the title compounds as a mixture that can be separated by means of HPLC .
  • the mono-N-oxide compound prepared in Example 1 was subjected to an assay to determine the Chk-1 inhibitory activity.
  • the Chk-1 assay was conducted at Upstate Ltd, Gemini Crescent, Dundee Technology Park, Dundee, DD2 ISW, UK in accordance with the protocol set out below.
  • CHKl (h) 5-10 mU
  • 8 mM MOPS pH 7.0, 0.2 mM EDTA, 200 ⁇ M KKKVSRS GLYRSP SMPENLNRPR, 10 mM MgAcetate and ⁇ -33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required).
  • the reaction is initiated by the addition of the MgATP mix.
  • reaction After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 5 ⁇ l of a 3% phosphoric acid solution. 10 ⁇ l of the reaction mixture is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting
  • the di-N-oxide compound of Example 1 exhibits 76% inhibition agaist Chk-1 at a concentration of 10 ⁇ M whereas the parent free base has an IC 50 of 53 nM against Chk-1.
  • Tablet Formulation A tablet composition containing a compound of the formula (1) is prepared by mixing 50 mg of the compound with 197 mg of lactose (BP) as diluent, and 3 mg magnesium stearate as a lubricant and compressing to form a tablet in known manner.
  • BP lactose
  • a capsule formulation is prepared by mixing 100 mg of a compound of the formula (1) with 100 mg lactose and filling the resulting mixture into standard opaque hard gelatin capsules.
  • a parenteral composition for administration by injection can be prepared by dissolving a compound of the formula (1) in water containing 10% propylene glycol to give a concentration of active compound of 1.5 % by weight. The solution is then sterilised by filtration, filled into an ampoule and sealed.
  • a parenteral composition for injection is prepared by dissolving in water a compound of the formula (1) (2 mg/ml) and mannitol (50 mg/ml), sterile filtering the solution and filling into sealable 1 ml vials or ampoules.
  • a formulation for i.v. delivery by injection or infusion can be prepared by dissolving the compound of formula (1) (e.g. in a salt form) in water at 20 mg/ml. The vial is then sealed and sterilised by autoclaving.
  • a formulation for i.v. delivery by injection or infusion can be prepared by dissolving the compound of formula (1) (e.g. in a salt form) in water containing a buffer (e.g. 0.2 M acetate pH 4.6) at 20mg/ml. The vial is then sealed and sterilised by autoclaving.
  • a buffer e.g. 0.2 M acetate pH 4.6
  • a composition for sub-cutaneous administration is prepared by mixing a compound of the formula (1) with pharmaceutical grade corn oil to give a concentration of 5 mg/ml.
  • the composition is sterilised and filled into a suitable container.
  • Aliquots of formulated compound of formula (1) are put into 50 ml vials and lyophilized.
  • the compositions are frozen using a one-step freezing protocol at (-45 0 C).
  • the temperature is raised to -10 0 C for annealing, then lowered to freezing at —45 0 C, followed by primary drying at +25 0 C for approximately 3400 minutes, followed by a secondary drying with increased steps if temperature to 50 0 C.
  • the pressure during primary and secondary drying is set at 80 millitor.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule (1) ou des sels, solvates ou tautomères de ceux-ci, où Y1 et Y2 sont tous deux N+-O- ou bien l'un de Y1 et de Y2 est N et l'autre est N+-O- ; G est CH2, O, NH, NHCO ou CONH ; A est un groupe (CH2)n où n vaut de 1 à 4 à condition que lorsque G est O ou NH, n vaille au moins 2 ; Q est N ou N+-O- ; V2 est un azote ou un groupe CR5 ; V3 est un azote ou un groupe CR5 ; V4 est un azote ou CH ; à condition que pas plus de deux éléments parmi V2, V3 et V4 ne soient un azote ; R1 et R2 sont identiques ou différents et chacun est un hydrogène ou un substituant R6 ; R3 et R4 sont identiques ou différents et chacun est un hydrogène ou un alkyle en C1-4 ; ou bien R3 et R4 avec l'atome d'azote auquel ils sont attachés forment un groupe azétidine, pyrrolidine, pipéridine, pipérazine, N-méthylpipérazine ou morpholine ; à condition que lorsque Q est N+-O-, alors R3 et R4 soient tous deux autres qu'un hydrogène ; R5 est un hydrogène ou un substituant R6 ; et R6 est tel que défini dans les revendications. Les composés de formule (1) sont réduits dans des conditions hypoxiques telles que celles rencontrées dans les cellules de tumeurs solides pour donner des composés qui inhibent ou modulent la kinase Chk-1.
PCT/GB2007/002918 2006-08-01 2007-08-01 N-oxydes de quinoléine et de quinoxaline en tant qu'inhibiteurs de la chk-1 WO2008015423A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82102906P 2006-08-01 2006-08-01
US60/821,029 2006-08-01
GB0615293A GB0615293D0 (en) 2006-08-01 2006-08-01 Pharmaceutical compounds
GB0615293.8 2006-08-01

Publications (1)

Publication Number Publication Date
WO2008015423A1 true WO2008015423A1 (fr) 2008-02-07

Family

ID=38657646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/002918 WO2008015423A1 (fr) 2006-08-01 2007-08-01 N-oxydes de quinoléine et de quinoxaline en tant qu'inhibiteurs de la chk-1

Country Status (1)

Country Link
WO (1) WO2008015423A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115719A1 (fr) 2009-04-02 2010-10-14 Æterna Zentaris Gmbh Dérivés de quinoxaline et leur utilisation pour traiter des troubles dus à des tumeurs bénignes ou malignes
US8716287B2 (en) 2010-05-13 2014-05-06 Sentinel Oncology Limited Pharmaceutical compounds
WO2015059088A1 (fr) 2013-10-23 2015-04-30 Bayer Cropscience Ag Dérivés de chinoxaline substitués servant d'agent de lutte antiparasitaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101444A1 (fr) * 2002-05-29 2003-12-11 Millennium Pharmaceuticals, Inc. Composes et derives de diaryluree utilises comme inhibiteurs de chk-1 dans le traitement du cancer
WO2006120573A2 (fr) * 2005-02-01 2006-11-16 Sentinel Oncology Limited N-oxydes heterocycliques utilises comme inhibiteurs de la proteine kinase lors d'une reduction selective dans un environnement hypoxique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101444A1 (fr) * 2002-05-29 2003-12-11 Millennium Pharmaceuticals, Inc. Composes et derives de diaryluree utilises comme inhibiteurs de chk-1 dans le traitement du cancer
WO2006120573A2 (fr) * 2005-02-01 2006-11-16 Sentinel Oncology Limited N-oxydes heterocycliques utilises comme inhibiteurs de la proteine kinase lors d'une reduction selective dans un environnement hypoxique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANDERSON ROBERT F ET AL: "Radical properties governing the hypoxia-selective cytotoxicity of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides.", ORGANIC & BIOMOLECULAR CHEMISTRY 7 JUN 2005, vol. 3, no. 11, 7 June 2005 (2005-06-07), pages 2167 - 2174, XP002458343, ISSN: 1477-0520 *
AZQUETA AMAIA ET AL: "DNA damage induced by a quinoxaline 1,4-di-N-oxide derivative (hypoxic selective agent) in Caco-2 cells evaluated by the comet assay.", MUTAGENESIS MAY 2005, vol. 20, no. 3, May 2005 (2005-05-01), pages 165 - 171, XP002458342, ISSN: 0267-8357 *
CHOWDHURY GOUTAM ET AL: "Enzyme-activated, hypoxia-selective DNA damage by 3-amino-2-quinoxalinecarbonitrile 1,4-di-N-oxide.", CHEMICAL RESEARCH IN TOXICOLOGY NOV 2004, vol. 17, no. 11, November 2004 (2004-11-01), pages 1399 - 1405, XP002458341, ISSN: 0893-228X *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115719A1 (fr) 2009-04-02 2010-10-14 Æterna Zentaris Gmbh Dérivés de quinoxaline et leur utilisation pour traiter des troubles dus à des tumeurs bénignes ou malignes
EP2241557A1 (fr) 2009-04-02 2010-10-20 Æterna Zentaris GmbH Dérivés de chinoxaline et leur utilisation pour le traitement de tumeurs bénignes et malignes
US8716287B2 (en) 2010-05-13 2014-05-06 Sentinel Oncology Limited Pharmaceutical compounds
WO2015059088A1 (fr) 2013-10-23 2015-04-30 Bayer Cropscience Ag Dérivés de chinoxaline substitués servant d'agent de lutte antiparasitaire

Similar Documents

Publication Publication Date Title
US8716287B2 (en) Pharmaceutical compounds
JP6162687B2 (ja) 新規のビスアミノキノリン化合物、それから調製した医薬組成物、及びそれらの使用
RU2262339C2 (ru) Производные индолил-3-глиоксиловой кислоты - соединения, обладающие противоопухолевой активностью, фармацевтическая композиция, противоопухолевое средство (варианты)
EP1948242B9 (fr) Composes cytotoxiques
US20090215777A1 (en) Pyrimidine Derivatives As HSP90 Inhibitors
JP2003510328A (ja) アゼピノインドール誘導体、その製法ならびに使用
US20080167309A1 (en) Pharmaceutical Compounds
EP2780331B1 (fr) Derives de pyrazine pharmaceutiquement actifs
US11001581B2 (en) Compounds which inhibit RNA polymerase, compositions including such compounds, and their use
US20090270416A1 (en) N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS Chk1 INHIBITORS FOR THE TREATMENT OF CANCER
CZ180599A3 (cs) 2-Imidazolinylaminoindolová sloučenina, farmaceutický prostředek ji obsahující a její použití
NZ336010A (en) Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
US11987568B2 (en) Allosteric inhibitor of WEE1 kinase
WO2008015423A1 (fr) N-oxydes de quinoléine et de quinoxaline en tant qu'inhibiteurs de la chk-1
WO2008015429A2 (fr) Composés pharmaceutiques
CN103664734B (zh) 杂环羟肟酸类化合物及其药用组合物和应用
US20110077305A1 (en) 5-lipoxygenase inhibitors
WO2008059259A2 (fr) Composés pharmaceutiques
WO2020051571A1 (fr) Inhibiteurs de brd4-jak2
JP6013498B2 (ja) リンパ増殖性悪性疾患の治療のためのホスファチジルイノシトール３−キナーゼ阻害剤としてのｎ−（３−｛［（３−｛［２−クロロ−５−（メトキシ）フェニル］アミノ｝キノキサリン−２−イル）アミノ］スルホニル｝フェニル）−２−メチルアラニンアミド
JP2000502351A (ja) 医薬化合物
KR100296643B1 (ko) 벤조퀴나졸린항엽산염과보호제의신규배합물
Kale et al. Benzimidazole: an important biological heterocyclic scaffold
US11897886B2 (en) Pyrazolo[4,3-d]pyrimidines as antitumor agents
IL92420A0 (en) Fused heterocyclic derivatives of 1,2,3,4-tetrahydroacridine,a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07766404

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07766404

Country of ref document: EP

Kind code of ref document: A1